Last reviewed · How we verify
IMVT-1402
IMVT-1402 is a neonatal Fc receptor (FcRn) antagonist that reduces circulating immunoglobulin levels by blocking FcRn-mediated recycling of IgG antibodies.
IMVT-1402 is a neonatal Fc receptor (FcRn) antagonist that reduces circulating immunoglobulin levels by blocking FcRn-mediated recycling of IgG antibodies. Used for Generalized myasthenia gravis (gMG), Thyroid eye disease (TED).
At a glance
| Generic name | IMVT-1402 |
|---|---|
| Sponsor | Immunovant Sciences GmbH |
| Drug class | FcRn antagonist |
| Target | FcRn (neonatal Fc receptor) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
FcRn is responsible for the recycling and prolonged half-life of IgG antibodies in the bloodstream. By antagonizing FcRn, IMVT-1402 increases the catabolism of pathogenic IgG autoantibodies, thereby reducing their circulating levels. This mechanism is intended to treat autoimmune diseases driven by IgG-mediated pathology.
Approved indications
- Generalized myasthenia gravis (gMG)
- Thyroid eye disease (TED)
Common side effects
- Infection (including upper respiratory tract infection)
- Infusion-related reactions
- Headache
Key clinical trials
- A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) (PHASE2)
- A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease (PHASE2)
- Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity (PHASE2)
- Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis (PHASE3)
- A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease (PHASE2)
- A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD) (PHASE2)
- IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PHASE2)
- A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMVT-1402 CI brief — competitive landscape report
- IMVT-1402 updates RSS · CI watch RSS
- Immunovant Sciences GmbH portfolio CI